Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma

Oncology (Switzerland)

Volumn 84, Issue 1, 2012, Pages 6-13

  Koschny, Ronald ^a   Gotthardt, Daniel ^a   Koehler, Christiane ^a   Jaeger, Dirk ^a   Stremmel, Wolfgang ^a   Ganten, Tom M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Diarrhea; Hepatocellular carcinoma; Skin rash; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CANCER INCIDENCE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; PYRIDINES; SKIN DISEASES; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 84867464777     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342425     Document Type: Article

References (28)

1. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 (Pubitemid 46890874)
2. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N: Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16- 24
3. Koschny R, Schmidt J, Ganten TM: Beyond Milan criteria - chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009; 23(suppl 21):49-60
4. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907- 1917 (Pubitemid 37518510)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
7. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300 (Pubitemid 46630787)
8. Worns MA, Weinmann A, Pfingst K, Schulte- Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Duber C, Otto G, Galle PR: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43: 489-495
9. Marrero JA, Lencioni R, Kudo M, Ye S, Nakajima K, Cihon F, Venook AP: Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29
10. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G: Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85-92
11. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 (Pubitemid 43112690)
12. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995- 2004
13. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM: Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501-1512.e2
14. Chen MH, Yang WL, Lin KT, Liu CH, Liu YW, Huang KW, Chang PM, Lai JM, Hsu CN, Chao KM, Kao CY, Huang CY: Gene expression- based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One 2011; 6:e27186
15. Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K: Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1604-1611
16. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX: Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-725
17. Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL: Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-4596
18. Saif MW, Merikas I, Tsimboukis S, Syrigos K: Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 2008; 9: 267- 274 (Pubitemid 351864886)
19. Song T, Zhang W, Wu Q, Kong D, Ma W: A single center experience of sorafenib in advanced hepatocellular carcinoma patients: Evaluation of prognostic factors. Eur J Gastroenterol Hepatol 2011; 23: 1233-1238
20. Bettinger D, Schultheiss M, Knuppel E, Thimme R, Blum HE, Spangenberg HC: Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2012; 56: 789-790
21. Mir O, Coriat R, Boudou-Rouquette P, Durand JP, Goldwasser F: Sorafenib-induced diarrhea and hypophosphatemia: Mechanisms and therapeutic implications. Ann Oncol 2012; 23: 280-281
22. Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F: Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2011, Epub ahead of print
23. Semrad TJ, Gandara DR, Lara PN Jr: Enhancing the clinical activity of sorafenib through dose escalation: Rationale and current experience. Ther Adv Med Oncol 2011; 3: 95-100
24. Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P: Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-1201
25. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S: Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4: 40-44
26. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodes J, Bruix J: Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67 (Pubitemid 29023987)
27. Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ: Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients. Am J Clin Oncol 1998; 21: 386-391 (Pubitemid 28366909)
28. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134 (Pubitemid 46089673)